Form 4: Pfizer Director Ronald E. Blaylock Reports Stock Purchase and Trust Transfer

Director Ronald E. Blaylock reports purchasing Pfizer shares and transferring shares to a trust.

Summary

• On February 13, 2025, Ronald E. Blaylock, a director of Pfizer Inc., reported a transaction involving the company's common stock.
• Blaylock purchased 19,457 shares at a price of $25.65 per share.
• Following the transaction, Blaylock directly owns 27,707 shares of Pfizer.
• Blaylock also indirectly owns 4,750 shares through a trust.
• The report was filed on February 14, 2025, by Esther Louis, acting under power of attorney for Ronald E. Blaylock.
• A power of attorney document was filed, granting Tara J. Gabbai, Lori P. Hernando, Esther H. Louis, Margaret M. Madden, Madelyn D. Purcell, Shanice A. Reid and Anika Reynolds the authority to act on Blaylock's behalf for SEC filings related to Pfizer securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The stock purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

Form 4, Pfizer, Director, Blaylock, Stock Purchase, Beneficial Ownership, Trust, PFE